Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Nodular formation in anti-laminin γ1 pemphigoid.

Tomura Y, Noto M, Ishii N, Hashimoto T, Manabe M, Osada SI.

J Dermatol. 2020 Jan 8. doi: 10.1111/1346-8138.15227. [Epub ahead of print] No abstract available.

PMID:
31916269
2.

Case of toxic shock syndrome triggered by negative-pressure wound therapy.

Tomura Y, Osada SI, Akama T, Hasunuma N, Nakae H, Manabe M.

J Dermatol. 2017 Dec;44(12):e315-e316. doi: 10.1111/1346-8138.14014. Epub 2017 Sep 1. No abstract available.

PMID:
28862320
3.

Original Research: Potential of urinary nephrin as a biomarker reflecting podocyte dysfunction in various kidney disease models.

Wada Y, Abe M, Moritani H, Mitori H, Kondo M, Tanaka-Amino K, Eguchi M, Imasato A, Inoki Y, Kajiyama H, Mimura T, Tomura Y.

Exp Biol Med (Maywood). 2016 Oct;241(16):1865-76. doi: 10.1177/1535370216651937. Epub 2016 May 22.

4.

Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats.

Kondo M, Tahara A, Hayashi K, Abe M, Inami H, Ishikawa T, Ito H, Tomura Y.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Oct;387(10):909-19. doi: 10.1007/s00210-014-1023-z. Epub 2014 Jul 23.

PMID:
25052043
5.

Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis.

Takakura K, Mizukami K, Mitori H, Noto T, Tomura Y.

Eur J Pharmacol. 2014 Aug 15;737:106-16. doi: 10.1016/j.ejphar.2014.05.015. Epub 2014 May 22.

PMID:
24858365
6.

Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.

Kakuta H, Kurosaki E, Niimi T, Gato K, Kawasaki Y, Suwa A, Honbou K, Yamaguchi T, Okumura H, Sanagi M, Tomura Y, Orita M, Yonemoto T, Masuzaki H.

J Pharmacol Exp Ther. 2014 Apr;349(1):10-20. doi: 10.1124/jpet.113.211722. Epub 2014 Jan 14.

PMID:
24424487
7.

[Pharmacological and clinical profile of bixalomer (Kiklin(®) capsules): a new therapeutic agent for hyperphosphatemia].

Taniguchi K, Kakuta H, Tomura Y, Kaku S, Uchida W.

Nihon Yakurigaku Zasshi. 2013 Jun;141(6):333-7. Review. Japanese. No abstract available.

PMID:
23749074
8.

Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells.

Takakura K, Tahara A, Sanagi M, Itoh H, Tomura Y.

Ren Fail. 2012;34(10):1309-16. doi: 10.3109/0886022X.2012.718955. Epub 2012 Sep 24. Erratum in: Ren Fail: 2012;34(10):1316.

PMID:
23002925
9.

Effects of high glucose on AVP-induced hyperplasia, hypertrophy, and type IV collagen synthesis in cultured rat mesangial cells.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

Endocr Res. 2012;37(4):216-27. doi: 10.3109/07435800.2012.671400. Epub 2012 May 17.

PMID:
22594926
10.

Downregulation of vasopressin V1A receptors and activation of mitogen-activated protein kinase in rat mesangial cells cultured under high-glucose conditions.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

Clin Exp Pharmacol Physiol. 2012 May;39(5):438-46. doi: 10.1111/j.1440-1681.2012.05693.x.

PMID:
22352691
11.

Synthesis and pharmacological evaluation of 2-(1-alkylpiperidin-4-yl)-n-[(1r)-1-(4-fluorophenyl)-2-methylpropyl]acetamide Derivatives as Novel Antihypertensive Agents.

Watanuki S, Matsuura K, Tomura Y, Okada M, Okazaki T, Ohta M, Tsukamoto S.

Chem Pharm Bull (Tokyo). 2012;60(2):223-34.

12.

Synthesis and pharmacological evaluation of 1-alkyl-N-[(1R)-1-(4-fluorophenyl)-2-methylpropyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents.

Watanuki S, Matsuura K, Tomura Y, Okada M, Okazaki T, Ohta M, Tsukamoto S.

Chem Pharm Bull (Tokyo). 2011;59(11):1376-85.

13.

Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents.

Watanuki S, Matsuura K, Tomura Y, Okada M, Okazaki T, Ohta M, Tsukamoto S.

Bioorg Med Chem. 2011 Sep 15;19(18):5628-38. doi: 10.1016/j.bmc.2011.07.030. Epub 2011 Jul 29.

PMID:
21875808
14.

Synthesis and pharmacological evaluation of 1-isopropyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel antihypertensive agents.

Watanuki S, Matsuura K, Tomura Y, Okada M, Okazaki T, Ohta M, Tsukamoto S.

Chem Pharm Bull (Tokyo). 2011;59(8):1029-37.

15.

Vasopressin regulates rat mesangial cell growth by inducing autocrine secretion of vascular endothelial growth factor.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

J Physiol Sci. 2011 Mar;61(2):115-22. doi: 10.1007/s12576-010-0128-5. Epub 2011 Jan 13.

PMID:
21229342
16.

Vasopressin induces human mesangial cell growth via induction of vascular endothelial growth factor secretion.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

Neuropeptides. 2011 Apr;45(2):105-11. doi: 10.1016/j.npep.2010.12.001. Epub 2010 Dec 31.

PMID:
21196048
17.

Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells.

Tahara A, Tsukada J, Tomura Y, Yatsu T, Shibasaki M.

Pharmacol Res. 2008 Feb;57(2):142-50. doi: 10.1016/j.phrs.2008.01.003. Epub 2008 Jan 20.

PMID:
18299204
18.

Effect of vasopressin on type IV collagen production in human mesangial cells.

Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M.

Regul Pept. 2008 Apr 10;147(1-3):60-6. doi: 10.1016/j.regpep.2008.01.002. Epub 2008 Jan 7.

PMID:
18258315
19.

Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells.

Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M.

Clin Exp Pharmacol Physiol. 2008 May;35(5-6):586-93. doi: 10.1111/j.1440-1681.2007.04852.x. Epub 2007 Dec 27.

PMID:
18177476
20.

Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy.

Tahara A, Tsukada J, Tomura Y, Suzuki T, Yatsu T, Shibasaki M.

Vascul Pharmacol. 2007 Jun;46(6):463-9. Epub 2007 Mar 1.

PMID:
17395547
21.

Binding and signal transduction characteristics of the nonpeptide vasopressin V1A receptor-selective antagonist YM218 in cultured rat mesangial cells.

Tahara A, Tsukada J, Tomura Y, Kusayama T, Momose K, Taniguchi N, Suzuki T, Yatsu T, Shibasaki M.

Pharmacology. 2006;78(2):81-90. Epub 2006 Sep 11.

PMID:
16966841
22.

Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells.

Tahara A, Tsukada J, Tomura Y, Momose K, Suzuki T, Yatsu T, Shibasaki M.

Eur J Pharmacol. 2006 May 24;538(1-3):32-8. Epub 2006 Apr 1.

PMID:
16678155
23.

Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats.

Uemura T, Takamatsu H, Kawasaki T, Taniguchi M, Yamamoto E, Tomura Y, Uchida W, Miyata K.

Eur J Pharmacol. 2006 Apr 24;536(1-2):154-61. Epub 2006 Mar 3.

PMID:
16566917
24.

Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.

Shimada Y, Taniguchi N, Matsuhisa A, Akane H, Kawano N, Suzuki T, Tobe T, Kakefuda A, Yatsu T, Tahara A, Tomura Y, Kusayama T, Wada K, Tsukada J, Orita M, Tsunoda T, Tanaka A.

Bioorg Med Chem. 2006 Mar 15;14(6):1827-37. Epub 2005 Nov 11.

PMID:
16290163
25.

Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group.

Shimada Y, Akane H, Taniguchi N, Matsuhisa A, Kawano N, Kikuchi K, Yatsu T, Tahara A, Tomura Y, Kusayama T, Wada K, Tsukada J, Tsunoda T, Tanaka A.

Chem Pharm Bull (Tokyo). 2005 Jul;53(7):764-9.

26.

Lead poisoning in whooper and tundra swans.

Nakade T, Tomura Y, Jin K, Taniyama H, Yamamoto M, Kikkawa A, Miyagi K, Uchida E, Asakawa M, Mukai T, Shirasawa M, Yamaguchi M.

J Wildl Dis. 2005 Jan;41(1):253-6.

PMID:
15827233
27.

Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.

Tsukada J, Tahara A, Tomura Y, Kusayama T, Wada K, Ishii N, Taniguchi N, Suzuki T, Yatsu T, Uchida W, Shibasaki M.

Vascul Pharmacol. 2005 Jan;42(2):47-55.

PMID:
15722249
28.

Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.

Tahara A, Tsukada J, Tomura Y, Kusayama T, Wada K, Ishii N, Taniguchi N, Suzuki T, Yatsu T, Uchida W, Shibasaki M.

Pharmacol Res. 2005 Mar;51(3):275-81.

PMID:
15661579
29.

Progression of renal failure with anaemia and multiple effects of angiotensin-converting enzyme inhibitor in rats with renal mass reduction.

Yatsu T, Sanagi M, Fujimori A, Tomura Y, Hayashi K, Tanahashi M, Inagaki O.

Pharmacol Res. 2003 Mar;47(3):243-52.

PMID:
12591020
30.

Alterations of renal vasopressin V1A and V2 receptors in spontaneously hypertensive rats.

Tahara A, Tsukada J, Tomura Y, Wada K, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

Pharmacology. 2003 Feb;67(2):106-12.

PMID:
12566855
31.

Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs.

Yatsu T, Kusayama T, Tomura Y, Arai Y, Aoki M, Tahara A, Wada K, Tsukada J.

Pharmacol Res. 2002 Nov;46(5):375-81.

PMID:
12419640
32.

Effect of YM471, a nonpeptide AVP receptor antagonist, on human coronary artery smooth muscle cells.

Tahara A, Tsukada J, Tomura Y, Wada K, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

Peptides. 2002 Oct;23(10):1809-16.

PMID:
12383869
33.

Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.

Wada K, Tahara A, Arai Y, Aoki M, Tomura Y, Tsukada J, Yatsu T.

Eur J Pharmacol. 2002 Aug 23;450(2):169-77.

PMID:
12206855
34.

Effect of YM471, an orally active non-peptide arginine vasopressin receptor antagonist, on human vascular smooth muscle cells.

Tahara A, Tsukada J, Tomura Y, Kusayama T, Wada K, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

J Hypertens. 2002 Sep;20(9):1807-14.

PMID:
12195123
35.

Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist.

Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Aoki M, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

Eur J Pharmacol. 2002 Jun 20;446(1-3):129-38.

PMID:
12098594
36.

In vivo visualization of characteristics of renal microcirculation in hypertensive and diabetic rats.

Yamamoto T, Tomura Y, Tanaka H, Kajiya F.

Am J Physiol Renal Physiol. 2001 Sep;281(3):F571-7.

37.

Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.

Tsukada J, Tahara A, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Taniguchi N, Tanaka A.

Br J Pharmacol. 2001 Jul;133(5):746-54.

38.

Direct in vivo visualization of glomerular microcirculation by intravital pencil lens-probe CCD videomicroscopy.

Yamamoto T, Hayashi K, Matsuda H, Tomura Y, Ogasawara Y, Hashimoto R, Tada T, Tanaka H, Kajiya F.

Clin Hemorheol Microcirc. 2000;23(2-4):103-8. Review.

PMID:
11321426
39.

Direct in vivo visualization of renal microcirculation by intravital CCD videomicroscopy.

Yamamoto T, Hayashi K, Tomura Y, Tanaka H, Kajiya F.

Exp Nephrol. 2001 Mar-Apr;9(2):150-5. Review.

PMID:
11150864
40.

Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells.

Tahara A, Tsukada J, Tomura Y, Wada Ki, Kusayama T, Ishii N, Yatsu T, Uchida W, Tanaka A.

Br J Pharmacol. 2000 Jan;129(1):131-9.

41.

[Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist].

Yatsu T, Tomura Y, Tahara A, Wada K, Kusayama T, Tsukada J, Tanaka A, Iizumi Y, Honda K.

Nihon Yakurigaku Zasshi. 1999 Oct;114 Suppl 1:113P-117P. Japanese.

PMID:
10629866
42.

Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences.

Tahara A, Tsukada J, Ishii N, Tomura Y, Wada K, Kusayama T, Yatsu T, Uchida W, Tanaka A.

Regul Pept. 1999 Oct 22;84(1-3):13-9.

PMID:
10535403
43.

Comparison of vasopressin binding sites in human uterine and vascular smooth muscle cells.

Tahara A, Tsukada J, Ishii N, Tomura Y, Wada K, Kusayama T, Yatsu T, Uchida W, Tanaka A.

Eur J Pharmacol. 1999 Jul 28;378(1):137-42.

PMID:
10478574
44.

Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.

Yatsu T, Tomura Y, Tahara A, Wada K, Kusayama T, Tsukada J, Tokioka T, Uchida W, Inagaki O, Iizumi Y, Tanaka A, Honda K.

Eur J Pharmacol. 1999 Jul 9;376(3):239-46.

PMID:
10448882
45.

Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats.

Tomura Y, Tahara A, Tsukada J, Yatsu T, Uchida W, Iizumi Y, Honda K.

Clin Exp Pharmacol Physiol. 1999 May-Jun;26(5-6):399-403.

PMID:
10386228
46.

Characterization of vasopressin receptor in rat lung.

Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A.

Neuropeptides. 1998 Jun;32(3):281-6.

PMID:
10189064
47.

Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells.

Tahara A, Saito M, Tsukada J, Ishii N, Tomura Y, Wada K, Kusayama T, Yatsu T, Uchida W, Tanaka A.

Eur J Pharmacol. 1999 Feb 26;368(1):89-94.

PMID:
10096773
48.

AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors.

Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A.

Pflugers Arch. 1999 Jan;437(2):219-26.

PMID:
9929562
49.

Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.

Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A.

Br J Pharmacol. 1998 Dec;125(7):1463-70.

50.

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.

Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W, Tanaka A.

Cardiovasc Res. 1998 Apr;38(1):198-205.

PMID:
9683922

Supplemental Content

Loading ...
Support Center